Bio-Rad Laboratories Management
Management criteria checks 2/4
Bio-Rad Laboratories' CEO is Norman Schwartz, appointed in Jan 2003, has a tenure of 22.33 years. total yearly compensation is $8.29M, comprised of 12.8% salary and 87.2% bonuses, including company stock and options. directly owns 4.46% of the company’s shares, worth $302.35M. The average tenure of the management team and the board of directors is 1.3 years and 8.1 years respectively.
Key information
Norman Schwartz
Chief executive officer
US$8.3m
Total compensation
| CEO salary percentage | 12.78% |
| CEO tenure | 22.3yrs |
| CEO ownership | 4.5% |
| Management average tenure | 1.3yrs |
| Board average tenure | 8.1yrs |
Recent management updates
Recent updates
Acquisition And Droplet Digital PCR Will Advance Oncology Diagnostics
May 13 Bio-Rad's efforts in digital PCR technology and strategic acquisitions aim to expand applications and bolster revenue through oncology diagnostics and rare mutation detection.Bio-Rad: With Low Debt And A Stock Price Drop, Is The Company Undervalued?
May 09Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Apr 10
Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
Mar 18Some Confidence Is Lacking In Bio-Rad Laboratories, Inc. (NYSE:BIO) As Shares Slide 28%
Feb 28Is There An Opportunity With Bio-Rad Laboratories, Inc.'s (NYSE:BIO) 39% Undervaluation?
Feb 18Bio-Rad: Uncertainties And Conservatism Continue To Hold Stock Back From Its Full Potential
Jan 29Getting In Cheap On Bio-Rad Laboratories, Inc. (NYSE:BIO) Is Unlikely
Jan 06Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Dec 16Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis
Nov 25Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?
Nov 25A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Nov 04Bio-Rad Laboratories: Overvalued Given Current Growth Prospects
Sep 23We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Sep 08Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon
Jul 18Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar
Jul 14Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Apr 14Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance
Oct 25Bio-Rad: A Cash Flow Returns On Investments Analysis
Aug 10Bio-Rad Labs reports Q4 2022 results
Feb 16Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
Jan 04Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M
Oct 27Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal
Oct 12Bio-Rad Laboratories hits 52-week low; down 40% YTD
Sep 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$2b |
| Dec 31 2024 | US$8m | US$1m | -US$2b |
| Sep 30 2024 | n/a | n/a | -US$779m |
| Jun 30 2024 | n/a | n/a | -US$1b |
| Mar 31 2024 | n/a | n/a | -US$322m |
| Dec 31 2023 | US$7m | US$1m | -US$637m |
| Sep 30 2023 | n/a | n/a | -US$159m |
| Jun 30 2023 | n/a | n/a | -US$428m |
| Mar 31 2023 | n/a | n/a | -US$191m |
| Dec 31 2022 | US$8m | US$1m | -US$4b |
| Sep 30 2022 | n/a | n/a | -US$6b |
| Jun 30 2022 | n/a | n/a | -US$2b |
| Mar 31 2022 | n/a | n/a | -US$91m |
| Dec 31 2021 | US$9m | US$988k | US$4b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$4b |
| Mar 31 2021 | n/a | n/a | US$4b |
| Dec 31 2020 | US$8m | US$987k | US$4b |
| Sep 30 2020 | n/a | n/a | US$4b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$7m | US$950k | US$2b |
| Sep 30 2019 | n/a | n/a | US$377m |
| Jun 30 2019 | n/a | n/a | US$905m |
| Mar 31 2019 | n/a | n/a | US$574m |
| Dec 31 2018 | US$8m | US$942k | US$366m |
Compensation vs Market: Norman's total compensation ($USD8.29M) is about average for companies of similar size in the US market ($USD8.54M).
Compensation vs Earnings: Norman's compensation has increased whilst the company is unprofitable.
CEO
Norman Schwartz (74 yo)
22.3yrs
Tenure
US$8,289,471
Compensation
Mr. Norman D. Schwartz was Principal Financial Officer of Bio-Rad Laboratories, Inc. since February 9, 2024 until April 15, 2024 and served as its Interim CFO until February 9, 2024. He serves as an Indepe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 22.3yrs | US$8.29m | 4.46% $ 302.4m | |
| President & COO | less than a year | US$4.31m | no data | |
| Executive VP & CFO | 1.1yrs | US$3.92m | 0.0031% $ 210.7k | |
| Executive Vice President of Global Commercial Operations | 10.4yrs | US$2.24m | 0.030% $ 2.0m | |
| Executive VP & President of the Clinical Diagnostics Group | less than a year | US$2.23m | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior Vice President and Chief Compliance & Privacy Officer | no data | no data | no data | |
| Executive VP | 1.3yrs | no data | no data | |
| Executive Vice President of Global Human Resources | 11.1yrs | no data | 0.068% $ 4.6m | |
| Senior Vice President of Global Commercial Operations - Asia Pacific | no data | no data | no data | |
| Executive VP & President of Life Science Group | no data | no data | 0.00054% $ 36.6k | |
| Senior Vice President of Global Commercial Operations of Europe | no data | no data | no data |
1.3yrs
Average Tenure
62yo
Average Age
Experienced Management: BIO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 30.3yrs | US$8.29m | 4.46% $ 302.4m | |
| Lead Independent Director | 8.1yrs | US$339.56k | 0.0011% $ 76.5k | |
| Director Emeritus | 3.1yrs | US$40.18k | 11.79% $ 798.9m | |
| Independent Director | 8.1yrs | US$326.56k | 0.0011% $ 76.5k | |
| Independent Director | 8.1yrs | US$311.56k | 0.0011% $ 76.5k | |
| Independent Director | 8.1yrs | US$331.56k | 0.0011% $ 76.5k | |
| Director | 3.1yrs | no data | 0.019% $ 1.3m |
8.1yrs
Average Tenure
66yo
Average Age
Experienced Board: BIO's board of directors are considered experienced (8.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 07:42 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bio-Rad Laboratories, Inc. is covered by 25 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Jon Wood | BofA Global Research |
| Sel Hardy | CFRA Equity Research |